Evidence map›Paper›PMID 39329651›Full record

ArticleBioengineering (Basel, Switzerland)2024

NMGrad: Advancing Histopathological Bladder Cancer Grading with Weakly Supervised Deep Learning.

Saul Fuster, Umay Kiraz, Trygve Eftestøl, Emiel A M Janssen, Kjersti Engan

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saul FusterDepartment of Electrical Engineering and Computer Science, University of Stavanger, 4021 Stavanger, Norway.ORCID 0009-0002-0285-6489
Umay KirazDepartment of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway.ORCID 0000-0002-6721-4877
Trygve EftestølDepartment of Electrical Engineering and Computer Science, University of Stavanger, 4021 Stavanger, Norway.ORCID 0000-0003-4487-7018
Emiel A M JanssenDepartment of Pathology, Stavanger University Hospital, 4011 Stavanger, Norway.ORCID 0000-0002-7760-5396
Kjersti EnganDepartment of Electrical Engineering and Computer Science, University of Stavanger, 4021 Stavanger, Norway.ORCID 0000-0002-8970-0067

Funding

European Union's Horizon 2020 research and 387 innovation program 860627
6 · The paper itself

Abstract

The most prevalent form of bladder cancer is urothelial carcinoma, characterized by a high recurrence rate and substantial lifetime treatment costs for patients. Grading is a prime factor for patient risk stratification, although it suffers from inconsistencies and variations among pathologists. Moreover, absence of annotations in medical imaging renders it difficult to train deep learning models. To address these challenges, we introduce a pipeline designed for bladder cancer grading using histological slides. First, it extracts urothelium tissue tiles at different magnification levels, employing a convolutional neural network for processing for feature extraction. Then, it engages in the slide-level prediction process. It employs a nested multiple-instance learning approach with attention to predict the grade. To distinguish different levels of malignancy within specific regions of the slide, we include the origins of the tiles in our analysis. The attention scores at region level are shown to correlate with verified high-grade regions, giving some explainability to the model. Clinical evaluations demonstrate that our model consistently outperforms previous state-of-the-art methods, achieving an F1 score of 0.85.

Indexed as

computational pathologydeep learninggradingmultiscaleurothelial carcinomaweakly supervised learning

Identifiers

PMID39329651
PMCPMC11428615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.